ERBB2 and breast cancer: The proportion of cases classified as high-level TILs decreased post-treatment across BC subtypes, although no pooled analysis was possible for the Luminal subtype due to the low number of studies (Not specified: pooled OR [95% CI] = 1.60 [95% CI: 1.12-2.30]; HER2-positive: pooled OR [95% CI] =1.88 [0.87-4.08); TNBC: pooled OR [95% CI] =1.05 [0.41-2.68].